BookJulio A. Aguirre-Ghiso, editor.
Summary: "This book focuses on the biological mechanisms of minimal residual disease (MRD) and recurrence. It integrates this biology in solid cancers and in hematological malignancies. It reports also on technological advancements for monitoring MRD, derived from mechanistic insights. Chapters in solid and hematological malignancies address stem cell biology, genetics, epigenetics and micro-environmental regulation of dormant MRD. Novel insight into technologies for molecular phenotyping of MRD and monitoring of CTCs, DTCs and cell free RNA and DNA are also addressed extensively. Five chapters explore the above concepts in solid cancers such as prostate, breast, melanoma, head and neck and esophageal. Two chapters also explore the basic mechanisms of vascular biology targeting and epigenetic mechanisms regulating pluripotency programs during dormancy. Similar biology is explored in hematological malignancies such as T-ALL, CML, AML and multiple myeloma in additional four chapters"--Publisher's description.
Contents:
Epigenetic and pluripotency aspects of disseminated cancer cells during minimal residual disease / Maria Jose Carlini, Nitisha Shrivastava, Maria Soledad Sosa
Anti-angiogenic therapy-mediated endothelial damage: a driver of breast cancer recurrence? / Laura Pisarsky, Cyrus M. Ghajar
Minimal residual disease in prostate cancer / Frank C. Cackowski, Russell S. Taichman
Minimal residual disease in head and neck cancer and esophageal cancer / Christoph Sproll, Georg Fluegen, Nikolas H. Stoecklein
Detection of minimal residual disease and its clinical applications in melanoma and breast cancer patients / Selena Y. Lin, Javier I. J. Orozco, Dave S. B. Hoon
Preservation of quiescent chronic myelogenous leukemia stem cells by the bone marrow microenvironment / Mansi Shah, Ravi Bhatia
Minimal residual disease in acute myeloid leukemia / Alexandra Gomez-Arteaga, Monica L. Guzman
Characteristics and therapeutic targeting of minimal residual disease in childhood acute lymphoblastic leukemia / Irmela Jeremias, Denis M. Schewe
Minimal residual disease in multiple myeloma: impact on response assessment, prognosis and tumor heterogeneity / Natalie Berger, Seunghee Kim-Schulze, Samir Parekh